Stocktoria
Zhengye Biotechnology Holding Ltd ZYBT
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2025-01-07
Chart by TradingView
3/9
Piotroski F — financial health
1.49
Altman Z″ — distress risk · grey
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Financials | |||
| Revenue | $16.6M | $186.4M | $211.7M |
| Gross profit | $3.4M | $12.5M | $117.5M |
| Operating income | -$10.1M | $2.3M | $45.0M |
| Net income | -$10.0M | $1.6M | $31.5M |
| Operating cash flow | $1.9M | $5.6M | $48.2M |
| Free cash flow | $1.8M | $3.8M | $40.8M |
| Total assets | $62.4M | $67.6M | $499.9M |
| Total liabilities | $18.6M | $19.3M | $160.6M |
| Shareholders' equity | $43.9M | $38.9M | $339.3M |
| Ratios | |||
| Gross margin | 20.5% | 6.7% | 55.5% |
| Operating margin | -60.6% | 1.2% | 21.3% |
| Net margin | -60.0% | 0.8% | 14.9% |
| FCF margin | 10.6% | 2.0% | 19.3% |
| Return on assets | -16.0% | 2.3% | 6.3% |
| Return on equity | -22.8% | 4.0% | 9.3% |
| Debt / equity | 0.03× | 0.02× | 0.03× |
| Current ratio | 1.14 | 1.31 | 1.26 |
| Revenue growth | -91.1% | -12.0% | — |
Why these scores methodology →
Piotroski F-score: 3/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 1.49 (grey)
- Working capital / assets 0.039
- Retained earnings / assets -0.05
- EBIT / assets -0.162
- Equity / liabilities 2.363
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001975641 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.